



CES 2017 – Announcement No. 1:

VISIOMED GROUP is revolutionizing telemedicine with VISIOCHECK®, the first mobile, connected telemedicine station in the world weighing under 300 grams

Paris, January 4, 2017

VISIOMED GROUP (FR0011067669 – ALVMG), a company specializing in new-generation medical electronics presents its very latest technological revolution at the CES in Las Vegas: VisioCheck® BW-X07HD. This is the first mobile, connected universal telemedicine station in the world weighing under 300 grams, integrating all the medical devices necessary for remote tele-monitoring of patient vitals anywhere and in any circumstances.

Concentrating the latest innovations from VISIOMED GROUP

VisioCheck® features several medical devices needed for the constant measurement of physiological vital signs:



- an arm-band blood pressure meter;
- a touchless thermometer equipped with ThermoFlash® technology;
- an electrocardiogram (5 electrodes, 7 derivations);
- a pulse oximeter;
- a blood sugar monitor.

VisioCheck® thus helps to simply, reliably and quickly take vital signs that are usually done during a classic medical consultation in a doctor's office or at home.



The medical devices integrated into VisioCheck® also allow for constant monitoring of certain physiological constants to create, for example, a polysomnogram (monitoring issues related to sleep, including apnea), EKG Holter or blood pressure Holter. In this case, the data collected can be sent to a medical supervision platform available 24/7.

VisioCheck® will soon integrate other innovative medical devices from the BewellConnect® line such as a spirometer, an electronic stethoscope and even a mini-biological analysis laboratory. Also, VisioCheck® aims to be interoperable and open to all other medical systems via a simple Low Energy Bluetooth® connection.

VisioCheck®: the new-generation health assistant

Equipped with a 4" 16-million-color touch LCD screen, a high-definition camera and a high-intensity flash, VisioCheck® can also film or photograph wounds, sores, injuries, trauma, and even scan the throat and tonsils, etc. and sent snapshots instantly and securely, or simply store the health data collected on a secured HDS-certified cloud server (authorized in France to host health data).

VisioCheck®: 298 grams of pure technology

No bigger than a smartphone and developed using Google's Android operating system, the VisioCheck® mobile, connected telemedicine station weighs 298g, also featuring all the functionalities of a smartphone. VisioCheck® allows for video conferencing via Wi-Fi or 2G/3G/4G networks and for sharing the data collected between health professionals or between patients and healthcare professionals

VisioCheck® has been designed to facilitate the daily medical practice of health professionals of all kinds, anywhere and in any circumstance (doctors, nurses, pharmacists, hospital staff, etc.), and is also meant for certain populations (the chronically ill, traveling employees, etc.) who need daily monitoring while remaining mobile.

As a IIA-class-certified medical device currently applying for CE certifications and registration with the FDA, VisioCheck® is an ultra-portable "all-in-one" scalable solution that facilitates, simplifies and improves the experience of all uses of telemedicine and connected health services.

The VISIOMED GROUP is planning for the commercial launch of VisioCheck® in mid-2017. It will be available either for suggested retail purchase price of €2,500 (excluding tax) plus monthly access to the services for a cost varying from €49 excluding tax to €79 excluding tax depending on the options desired by the user, or only through a monthly subscription fee of €199 excluding tax to €249 excluding tax depending on the options selected.

VisioCheck®: the ideal solution to fight against insufficient medical coverage areas

The VisioCheck® will first be deployed in health institutions (retirement homes, hospitals, clinics, health centers, pharmacies, with nurses, etc.) but is also meant to be commercialized to insurance companies, assisters and large companies.

Beyond this, VisioCheck® is linked to a platform of doctors available 24/7, and is the perfect tool to respond to and fight against areas with insufficient medical coverage. Every town can now have an affordable telemedicine stations to let inhabitants be monitored and consult with doctors remotely, at any time.



New generation medical technology

VisioCheck®: the multipurpose telemedicine tool for all healthcare professionals

The VisioCheck® is an actual mobile, connected telemedicine station that facilitates all uses of telemedicine, both in freelance and hospital situations, in terms of:

- tele-expertise between healthcare professionals,
- tele-consultation between patients and healthcare professionals,
- tele-monitoring between patients and medical platforms.

A preview of this innovation is being presented at the CES in Las Vegas, while in the Official Journal, a decree has just been published pertaining to the coverage of treatment of certain long-term afflictions by tele-monitoring. This decree, which is an extension of Article 47 of the Law for Funding Social Security in 2017, will help to specify the funding of telemedicine.

The law allows doctors to be able to take part in teleconsultation and/or tele-expertise in certain regions for patients suffering from certain long-term afflictions, i.e. those suffering from chronic illness. Teleconsultations are paid based on the rates set by the Ministerial Order of April 26, 2016, or €26.00 to €43.70 per consultation depending on the doctor's specialty, or €3 more than traditional rates.

Currently, the Order covers three chronic pathologies, which are chronic heart failure, chronic respiratory failure and dialysis and transplanted kidney failure. A new Order is expected in early 2017 pertaining to complex diabetes.

Eric Sebban, the Founder and CEO of VISIOMED GROUP says, *“With this new connected medical device, the VISIOMED GROUP simply wants to revolutionize the practice of telemedicine. We have always been a partner to healthcare professionals in designing each of our medical devices. With the creation of VisioCheck®, we have come up with a universal and mobile system for doctors to facilitate the practice of medicine while traveling or working remotely.”*

Discover VisioCheck® live at www.bewell-connect.com

You can discover VisioCheck® and all the innovations presented by the teams at BewellConnect® at the CES in Las Vegas through the **Direct Live** system, exceptionally available on the website www.bewell-connect.com.

About VISIOMED GROUP

Founded in 2007 by Eric Sebban, the VISIOMED GROUP is a company specialized in new-generation medical electronics. The laboratory develops and markets innovative health products in the promising areas of medical self-diagnostics and well-being. VISIOMED is known as the inventor of the Thermo**Flash**®, the first clinical, infrared non-contact thermometer.

VISIOMED products incorporate innovation, technology and design to provide solutions for prevention and non-drug treatments based on simplicity, comfort and the well-being of users.

In 2014, the VISIOMED GROUP announced the launch of its “BewellConnect®” range of healthcare products, becoming the first medical electronics laboratory to penetrate the very high-potential market of the Internet of Things (IoT).

Based in Paris, the VISIOMED GROUP relies on a team of 105 employees including sales forces dedicated to commercialization in pharmacies (OTC), among health professionals (hospitals, clinics and retirement homes) and, since late 2010, mass distribution. In 2014, the Group generated revenue of more than €13 million. VISIOMED GROUP was described as an “Innovative Business” by Bpifrance.

VISIOMED GROUP was ranked 2nd in the national competition at the 2014 edition of Deloitte In Extensio Technology Fast 50 and 2nd in Europe in the Health/Biotech/Pharma sector of Deloitte Technology Fast 500. In 2016, the VISIOMED GROUP

More information at www.visiomed-lab.com.

Contacts



New generation medical technology

VIOMED GROUP

Eric Sebban

bourse@visiomed-lab.com

CEO

01 40 67 06 50

ACTUS finance & communication

Jérôme Fabreguettes-Leib

visiomed@actus.fr

Investor Relations

01 53 67 36 78

Alexandra Prisa

aprisa@actus.fr

Financial Press Relations

01 53 67 36 90



New generation medical technology